Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
41.20
-0.28 (-0.68%)
Official Closing Price
Updated: 6:30 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bristol-Myers Squibb
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
August 10, 2022
NetworkNewsWire Editorial Coverage New York, NY – August 10, 2022 – In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill...
Via
FinancialNewsMedia
Exposures
Product Safety
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
August 10, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 Highlights
August 03, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma
July 29, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
July 27, 2022
From
Bristol Myers Squibb
Via
Business Wire
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
July 26, 2022
Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could...
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma
July 22, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Teams Up with Jack and Jill of America Inc. to Expand Tomorrow’s Innovators Program to Increase Black Representation in the Healthcare Industry
July 21, 2022
From
Bristol Myers Squibb
Via
Business Wire
Get These 3 Juicy Dividend Yields While They Last
July 21, 2022
A good strategy for this unprecedented backdrop may be to bunker down with steady dividend paying companies that are likely to trend higher as market conditions improve. Compared to what was available...
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Bristol Myers Squibb Launches Disability Diversity in Clinical Trials (DDiCT) Initiative to Improve Healthcare Outcomes for People with Disabilities
July 20, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Extension of Turning Point Tender Offer
July 19, 2022
From
Bristol Myers Squibb
Via
Business Wire
U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
June 24, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
June 24, 2022
From
Bristol Myers Squibb
Via
Business Wire
New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)
June 24, 2022
From
Bristol Myers Squibb
Via
Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
June 20, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend
June 15, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors
June 15, 2022
From
Bristol Myers Squibb
Via
Business Wire
As Health Problems Mount Patients Welcome New Treatments
June 14, 2022
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,...
Via
FinancialNewsMedia
Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022
June 08, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
June 07, 2022
From
Bristol Myers Squibb
Via
Business Wire
Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
June 06, 2022
From
Bristol Myers Squibb
Via
Business Wire
Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
June 06, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
June 03, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
June 03, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19
June 02, 2022
From
Bristol Myers Squibb
Via
Business Wire
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
June 02, 2022
From
Bristol Myers Squibb
Via
Business Wire
Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus
June 01, 2022
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 27, 2022
From
Bristol Myers Squibb
Via
Business Wire
Data from Phase 2 PILOT Study of Bristol Myers Squibb’s CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
May 26, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in Bernstein’s 38th Annual Strategic Decisions Conference
May 26, 2022
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.